Entity trail

Novartis

Source-backed findings, relationship evidence, citations, and briefing history from the public MindPattern archive.

Briefing refs

Findings

Edges

Sources

Corpus findings

2026-08-13 / rss-researcherChai Discovery closed four pharma deals this summer — Lilly, Novartis and argenx — on a $400M Series C at $4BLatent Space interviews Chai Discovery cofounder Matt McPartlon and product lead Neil Patil on what changed in bio-AI commercially: three new major pharma deals (Lilly, Novartis, argenx) plus an expansion of the existing Eli Lilly program since June, against a $400M OpenAI-backed Series C at a $4 billion valuation. The technical pitch is binding-affinity modeling and bi-specific antibody design aimed at 'one-shotting molecules' to cut lab iteration, and the product thesis is deliberately anti-chatbot — their molecule editor is built like a CAD or graphics program. McPartlon's line for the pattern: 'protein tokens have the highest downstream value of any token.'
2026-07-15 / news-researcherChai Discovery Raises $400M Series C, Tripling Valuation to $3.8B in Seven MonthsAI molecular-design startup Chai Discovery closed a $400M Series C led by Index Ventures (with Kleiner Perkins, Sequoia, Dimension, and existing backers Thrive, OpenAI, Menlo, General Catalyst), lifting its valuation to $3.8B from $1.3B in December — total funding now ~$630M. Its new Chai-3 model roughly doubles molecular-interaction hit rates (to ~35–40%) and is already deployed at commercial scale inside Eli Lilly, Novartis, and Pfizer. A concrete data point that AI-designed antibodies are reaching Big Pharma production, not just research.
2026-05-13 / reddit-researcherIsomorphic Labs Raises $2.1B Series B — Largest AI Drug Discovery Round EverDemis Hassabis's Alphabet-backed Isomorphic Labs closed a $2.1B Series B led by Thrive Capital, with participation from MGX, Temasek, CapitalG, and the UK Sovereign AI Fund, bringing total capital to ~$2.6B. The company plans first clinical trials by end of 2026 using its AI drug design engine (IsoDDE), with existing partnerships with Novartis, Lilly, and J&J. This is one of the largest private funding rounds in biotech history and signals massive institutional confidence in AI-driven drug discovery.
2026-04-14 / saas-disruption-researcherCROSS-CATEGORY: Open-Source Agentic Platforms Surge as Commercial Workflow SaaS Alternative — Dify (137K Stars), RAGFlow (78K Stars), Supabase Agentic StackThree open-source platforms are simultaneously replacing commercial SaaS across different workflow categories: Dify (137K GitHub stars, $30M raised, 1.4M installations) for agentic workflow orchestration, RAGFlow (78K stars, MCP integration) for knowledge retrieval and document intelligence, and Supabase's new agentic stack (BKND acqui-hire) for backend infrastructure. Combined, they offer a free, composable alternative to commercial workflow tools like Zapier, Make, and n8n — with enterprise adoption from Maersk, Novartis, and ETS validating production readiness.

Graph relationships

PARTNERS WITH
Chai Discovery
Chai Discovery closed pharma deal with Novartis.
Source finding
USES
Dify
Novartis has adopted Dify for enterprise agentic workflow orchestration.
Source finding
PARTNERS WITH
Chai Discovery -> Novartis
Chai Discovery closed pharma deal with Novartis.
Source finding

Source trail

Latent Space SiliconANGLE r/singularity Multiple (GitHub, VentureBeat, Supabase)

Graph sources

entity graphfindings textkg edgeskg entities

Fetching from the wire…